Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The most commonly reported adverse events in the Phase 2 trial were gastrointestinal in nature, including nausea, vomiting, and diarrhoea consistent with the GLP-1 receptor agonist class
Goal: Investigate dual growth-hormone-axis stimulation and body-composition effects theoretical synergy that is not validated for this blend
Peptides of similar size show highly variable nasal absorption depending on molecular weight, charge, and formulation excipients
Formulation: BP-C1-57 (10mg), TB-500 (10mg), GHK-Cu (50mg), KPV (10mg)
US$ 26.09
US$ 22.93
US$ 22.28
US$ 23.75
US$ 24.59
US$ 25.48
US$ 23.81
US$ 21.79
US$ 29.68
US$ 21.72
